PHILADELPHIA, May 7, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced its participation in the following upcoming conferences.
American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting in New Orleans, LA
-
Clinical data from the ongoing Phase 1/2 study of the Company's TARGTEPOTM (Transduced Autologous Restorative Gene Therapy) system showing sustained production of erythropoietin (EPO) in patients with end stage renal disease
- Clinical Trial Showing EPO-Independence for 7 Months by Prolonged Secretion of Autologous EPO by TARGT – Abstract #29
- Session: Hematologic and Immunologic Diseases: Clinical Trials and Observations
- Oral Presentation – Wednesday, May 13, 2015 at 11:30 a.m. CDT
-
Preclinical data from the TARGT peptide platform showing sustained in vitro secretion levels of GLP-2
- TARGT Shows Sustained Secretion of the Therapeutic Peptide GLP-2 Which Retains Functional Activity in SCID Mice and Rats – Abstract #180
- Session: Diabetes, Metabolic and Genetic Diseases I
- Poster Presentation – Wednesday, May 13, 2015 at 5:15 p.m. CDT
Piper Jaffray GenomeRx Symposium in New York, NY
- Dr. Garry Neil, Chief Scientific Officer, will participate in a panel entitled Cellular Therapies: Toolkits and Platforms at the New York Palace Hotel on Wednesday, May 20, 2015 at 11:50 a.m. EDT
About Medgenics, Inc.
Medgenics is developing the TARGT™ (Transduced Autologous Restorative Gene Therapy) system, a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides using ex vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.